Triheptanoin in Pyruvate Dehydrogenase Deficiency

Journal of Pediatric Neurology 2021; 19(01): 065-068
DOI: 10.1055/s-0040-1714069

Letter to the Editor

¹Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

References
1 Patel KP, O'Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol Genet Metab 2012; 106 (03) 385-394
2 Mellick G, Price L, Boyle R. Late-onset presentation of pyruvate dehydrogenase deficiency. Mov Disord 2004; 19 (06) 727-729
3 Barnerias C, Saudubray JM, Touati G. et al. Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis. Dev Med Child Neurol 2010; 52 (02) e1-e9
4 Sofou K, Dahlin M, Hallböök T, Lindefeldt M, Viggedal G, Darin N. Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes. J Inherit Metab Dis 2017; 40 (02) 237-245
5 Mochel F. Triheptanoin for the treatment of brain energy deficit: A 14-year experience. J Neurosci Res 2017; 95 (11) 2236-2243
6 Chapel-Crespo CC, Lala S, Prasun P. Severe brain malformations in an infant with pyruvate dehydrogenase deficiency and Down syndrome. Pediatr Neurol 2017; 75: 101-102
7 Wehbe Z, Tucci S. Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases. J Inherit Metab Dis 2019(e-pub ahead of print)
8 Adanyeguh IM, Rinaldi D, Henry PG. et al. Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology 2015; 84 (05) 490-495